Life Sciences Q3 2026 Review Highlights Bioprinting Growth and Expanding Cardiovascular Device Demand

News originally published by

GlobeNewswire

“BCC Research highlights bioprinting reaching $5.1 billion by 2030 at a 16.1% CAGR, PBMCs rising to $577.2 million by 2031, and cardiovascular devices reaching $101.6 billion by 2030 as innovation accelerates across cell biology and medical technologies.”

Boston, Nov. 20, 2026 (GLOBE NEWSWIRE) -- The global life sciences industry continues to demonstrate robust structural momentum heading into the back half of 2026, underpinned by accelerating adoption of precision oncology therapies, AI-driven diagnostics, and expanding healthcare infrastructure across emerging markets. BCC Research's newly published State of the Life Sciences Industry – 2026 Third Quarter Review provides a comprehensive assessment of the forces reshaping the industry's competitive and investment landscape.

Key Findings

• Broad-based growth across life sciences verticals is being driven by rising incidence of hematologic cancers — including leukemia, lymphoma, and myeloma — particularly among aging populations, which is expanding the addressable patient pool for blood cancer therapeutics, liquid biopsy platforms, and precision oncology tools.
• North America remains the dominant regional market, supported by advanced healthcare infrastructure, high insurance penetration, strong regulatory frameworks, and leadership in CAR-T therapy and digital health adoption, while emerging markets in Asia-Pacific and Latin America represent the fastest-growing opportunity pools.
• The shift from chemotherapy to targeted and cell-based oncology therapies — including CAR-T cell therapies and bispecific antibodies — is commanding premium pricing and expanding revenues across the therapeutics segment, particularly in relapsed or refractory blood cancer indications where unmet clinical need remains significant.
• AI integration across drug discovery, clinical trials, and diagnostics is compressing development timelines, reducing costs, and enabling personalized treatment pathways — drawing sustained capital deployment from pharmaceutical, diagnostics, and medical device companies alike. Regulatory mandates supporting EHR adoption and healthcare digitization are further accelerating this structural shift.
• Noninvasive diagnostics and liquid biopsy are gaining significant clinical traction, with microfluidics, nanotechnology-based biomarker detection, CRISPR-based diagnostics, and AI-enhanced analysis emerging as next-generation enablers. Spatial omics, virtual AI staining in digital pathology, and long-read sequencing technologies for HLA typing represent additional high-conviction innovation vectors.
• Key players shaping the competitive landscape include Bristol Myers Squibb, AstraZeneca, Roche, Amgen, Johnson & Johnson, AbbVie, Sanofi, GSK, and Regeneron in therapeutics; Guardant Health, Foundation Medicine, Exact Sciences, Illumina, Oxford Nanopore Technologies, and Freenome in liquid biopsy and genomics; Labcorp, Quest Diagnostics, Eurofins Scientific, and Sonic Healthcare in laboratory services; and Medtronic, Boston Scientific, Abbott Laboratories, and Insulet across medical devices and outpatient care.

Market Drivers

The convergence of oncology innovation, digital transformation, and demographic-driven demand is creating durable, compounding growth conditions across life sciences subsectors. Rising cancer incidence — particularly among elderly populations — is simultaneously expanding demand for therapeutics, diagnostics, and pathology services. The migration toward outpatient and ambulatory surgical settings, driven by cost efficiency imperatives and minimally invasive procedural advances, is accelerating adoption of purpose-built digital workflow systems and enabling companies such as AngioDynamics and CareDx to scale within specialized care environments.
Topical drug delivery is emerging as a strategically differentiated segment, as patient adherence challenges, systemic side effects, and first-pass metabolism losses shift clinical and commercial preference toward targeted delivery alternatives. Companies including Hisamitsu Pharmaceutical, Glenmark Pharmaceuticals, Galderma, Kenvue, Bausch Health, and Haleon are positioned to capture this shift, while 3D bioprinting firms — including Aspect Biosystems, Cellbricks, 3D Systems, and Stratasys — are advancing toward near-term clinical translation despite current vascularization and GMP scalability constraints.

Investment Considerations

Investors evaluating life sciences exposure in 2026 should weigh a landscape defined by high-reward innovation cycles against persistent structural headwinds. CAR-T and bispecific antibody platforms carry premium revenue potential, but high treatment costs limit penetration in lower-income markets. Patent expirations across branded biologics — compounded by trade tariff disruptions and biosimilar competition — present margin compression risks for large-cap incumbents. Cybersecurity vulnerabilities in digital health infrastructure and the global shortage of trained pathologists represent operational constraints that could temper near-term EHR and digital pathology scalability. Companies best positioned for sustained outperformance include those with diversified oncology pipelines, AI-embedded diagnostic platforms, and emerging market distribution capabilities — among them Roche, AstraZeneca, Illumina, Guardant Health, and Exact Sciences.

About the Report

State of the Life Sciences Industry – 2026 Third Quarter Review delivers comprehensive market sizing, segmentation analysis, competitive intelligence, and forward-looking forecasts across key life sciences verticals including blood cancer therapeutics, liquid biopsy, digital pathology, electronic health records, outpatient surgical procedures, topical drug delivery, 3D bioprinting, and cell and gene therapy support services.

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.


BCC Research LLC
50 Milk St., Ste. 16, Boston, MA 02109
press@bccresearch.com  |  +1 781-489-7301
www.bccresearch.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthcare Times Utah

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.